261 related articles for article (PubMed ID: 32207067)
1. Malignancy Rates in Brodalumab Clinical Studies for Psoriasis.
Gottlieb A; Lebwohl M; Liu C; Israel RJ; Jacobson A
Am J Clin Dermatol; 2020 Jun; 21(3):421-430. PubMed ID: 32207067
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
McMichael A; Desai SR; Qureshi A; Rastogi S; Alexis AF
Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
Puig L; Lebwohl M; Bachelez H; Sobell J; Jacobson AA
J Am Acad Dermatol; 2020 Feb; 82(2):352-359. PubMed ID: 31175909
[TBL] [Abstract][Full Text] [Related]
6. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.
Lebwohl MG; Papp KA; Marangell LB; Koo J; Blauvelt A; Gooderham M; Wu JJ; Rastogi S; Harris S; Pillai R; Israel RJ
J Am Acad Dermatol; 2018 Jan; 78(1):81-89.e5. PubMed ID: 28985956
[TBL] [Abstract][Full Text] [Related]
7. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
Gottlieb AB; Gordon K; Hsu S; Elewski B; Eichenfield LF; Kircik L; Rastogi S; Pillai R; Israel R
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1305-1313. PubMed ID: 29512200
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
Papp KA; Griffiths CE; Gordon K; Lebwohl M; Szapary PO; Wasfi Y; Chan D; Hsu MC; Ho V; Ghislain PD; Strober B; Reich K; ; ;
Br J Dermatol; 2013 Apr; 168(4):844-54. PubMed ID: 23301632
[TBL] [Abstract][Full Text] [Related]
9. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
10. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3.
Warren RB; Hansen JB; Reich K; Paul C; Puig L
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):450-457. PubMed ID: 32662540
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
Lebwohl MG; Blauvelt A; Menter A; Papp KA; Guenthner S; Pillai R; Israel RJ; Jacobson A
Am J Clin Dermatol; 2019 Dec; 20(6):863-871. PubMed ID: 31493163
[TBL] [Abstract][Full Text] [Related]
12. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
[TBL] [Abstract][Full Text] [Related]
13. Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2018 Mar; 78(4):495-504. PubMed ID: 29516365
[TBL] [Abstract][Full Text] [Related]
14. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials.
Hsu S; Green LJ; Lebwohl MG; Wu JJ; Blauvelt A; Jacobson AA
Br J Dermatol; 2020 Apr; 182(4):880-888. PubMed ID: 31276189
[TBL] [Abstract][Full Text] [Related]
15. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
Puig L
Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and skin clearance recapture in clinical studies of brodalumab.
Bagel J; Lebwohl M; Israel RJ; Jacobson A
J Am Acad Dermatol; 2020 Feb; 82(2):344-351. PubMed ID: 31175910
[TBL] [Abstract][Full Text] [Related]
17. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
[TBL] [Abstract][Full Text] [Related]
18. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
Papp KA; Reich K; Paul C; Blauvelt A; Baran W; Bolduc C; Toth D; Langley RG; Cather J; Gottlieb AB; Thaçi D; Krueger JG; Russell CB; Milmont CE; Li J; Klekotka PA; Kricorian G; Nirula A
Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
[TBL] [Abstract][Full Text] [Related]
19. Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials.
Reich K; Thaçi D; Stingl G; Andersen JS; Hiort LC; Lexner MO; Winkler D; Paul C
Acta Derm Venereol; 2022 Mar; 102():adv00683. PubMed ID: 35191512
[TBL] [Abstract][Full Text] [Related]
20. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]